Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..